Life Extension Spring Clearance Sale

Life Extension Magazine

LE Magazine March 2000
image


Overlooked & Overworked
Preventive maintenance for your stomach, liver and pancreas

by Karin Granstrom Jordan, MD

Fibrosis, cirrhosis and alcohol
A characteristic feature of liver disease, regardless of its cause, is the increased deposition of collagen, the connective tissue protein. This increased collagen accumulation could result from enhanced collagen biosynthesis and/or decreased collagen breakdown. PPC appears to increase collagen breakdown by stimulating collagenase activity in hepatic stellate cells preventing the development of fibrosis and cirrhosis (Li J et al., 1992). Several studies have focused on PPC and its effect on collagen and fibrosis.

A baboon study (Lieber CS et al., 1994) confirmed earlier results (Lieber CS et al., 1990) showing that in the baboon, feeding of ethanol (a form of alcohol) results in hepatic fibrosis and cirrhosis even when associated with an adequate diet. This effect could be prevented by supplementing the diet with a 94-96% pure PPC preparation. None of the eight animals fed alcohol with PPC for up to 6.5 years had progression to fibrosis or cirrhosis as had 10 of 12 unsupplemented baboons, a highly significant difference. Another study (Ma X et al., 1996) revealed that PPC reduces hepatic fibrosis induced by either carbon tetrachloride or human albumin in rats, and that PPC not only prevents the development of fibrosis but accelerates the regression of pre-existing fibrosis. The study further suggested that the protective effect exerted by PPC against fibrosis is due, at least in part to increased collagen breakdown.

One of the ways PPC helps prevent liver damage from alcohol is by inhibiting an enzyme known as CYP 2E1. Chronic alcohol consumption raises levels of this enzyme, which is involved in the metabolism of alcohol. This leads to oxidative stress and acetaldehyde production, which stresses the antioxidant defense system and depletes glutathione. CYP 2E1 also furthers the production of toxic metabolites from common drugs such as acetaminophen and promotes carcinogenesis. CYP 2E1 inhibitors protect the liver from alcohol-induced damage, but drugs tested for this purpose have been too toxic for practical use. However it has recently been discovered that PPC significantly inhibits CYP 2E1 activity (Lieber CS, 1999; Aleynik MK et al., 1999), providing a potential nontoxic solution to this problem.

Antioxidant effects
As we have seen, a key mechanism of PPC action is its antioxidant effect. Despite its rich content of polyunsaturated linoleic acid, PPC has been shown to effectively reduce oxidative stress caused by alcohol in the liver and pancreas, as well as in LDL cholesterol.

Newly published research (Aleynik SI, Leo MA, Takeshige U et al., 1999) identifies the constituent of PPC primarily responsible for its antioxidant effect. This constituent, DLPC, comprises 40-52% of PPC. The researchers found that the "remarkable" antioxidant effect of PPC on oxidative stress induced in hepatoma cells by arachidonic acid could be accounted for by the DLPC contained in it.

DLPC appears to be primarily responsible for many of the protective actions of PPC on the liver and pancreas. A new study demonstrates that DLPC stimulates the Kupffer cells of the liver to decrease production of the hepatotoxic tumor necrosis factor-a, while increasing production of the hepatoprotective interleukin-1b (Oneta CM et al., 1999). DLPC also appears to decrease activation of collagen-producing stellate cells in the liver, and to increase collagenase activity and thus collagen breakdown, asdiscussed above.

The benefits of protection
Modern living unfortunately involves daily exposure to substances that are toxic to our bodies, which can impose heavy stresses on the vital organs we have discussed. Therefore it is logical to think that all of us can benefit from some kind of support in maintaining the vitality of these organs. In particular, individuals with a substantial alcohol consumption, with obesity, diabetes or with high exposure to NSAIDs or environmental toxins have an even greater reason to take protective measures because of the documented risk of developing serious pathologies.

Knowing that conventional medicine has very little to offer in the prevention or early treatment of the disorders we have discussed, it seems wise to remember that prevention is the best cure. We are fortunate today to have access to a natural protective remedy that is safe, effective and without significant side effects.

And it is good to know that protection of the liver, pancreas and stomach is beneficial not only for these vital organs themselves, but for the overall health and vitality of our body.

Obesity and Steatohepatitis
Among the causes for non-alcoholic steatohepatitis (NASH), obesity is considered to be the most common. There is evidence to suggest that liver disease actually can be considered a complication of obesity. No major prospective longitudinal studies of NASH have been carried out. It seems, however, that the risk of progression to cirrhosis is generally low for non-obese individuals but significant among obese individuals. There is no predictable correlation between symptoms (or lack of them), abnormality of liver function tests and severity of liver tissue damage.

In a study of 50 unselected, obese (21-130% above ideal body weight) subjects admitted to the hospital for weight reduction, Braillon et al (1985) found that 10% had normal livers, 48% fatty livers, 26% steatohepatitis, 8% fibrosis and 8% cirrhosis.

Interestingly, it has been observed among patients with fatty liver related to obesity, that rapid weight loss caused by dieting and intestinal bypass surgery increase the risk for developing steatotohepatitis. The resulting increase in the concentration of fatty acids and/or ketones within the liver severely augments the generation of free radicals (Day CP et al.: 1994).

A study by Yang et al (1997) indicates that obesity also increases susceptibility to endotoxin-mediated liver injury. Endotoxins are cell wall components produced by intestinal gram-negative bacteria, thought to play a role in liver injury induced by alcohol and other hepatotoxins. Under normal conditions they are absorbed into the portal venous circulation and detoxified in the liver. Hepatic dysfunction will interfere with this clearing mechanism and amplify the negative activities of endotoxin, such as lipid peroxidation, reduced detoxification by the cytochrome P-450 enzymes, and impairment of the immune system.

Berson et al., 1998 summarizes the insights from the new research on the mechanisms of steatohepatitis well: Its development requires a double hit, the first producing steatosis, the second a source of oxidative stress capable of initiating significant lipid peroxidation. This concept provides a rationale for both the treatment and prevention of disease progression in steatosis of alcoholic and non-alcoholic causes. Management strategies should ideally be directed at reducing the severity of steatosis and at avoiding and removing the triggers of inflammation and fibrosis. Specific treatment modalities for at-risk individuals might include sensible weight reduction, cessation of exposure to toxins and treatment with antioxidants and inhibitors of peroxisomal b-oxidation.

PPC in hepatitis
PPC has been found to decrease serum aminotransferases in experimental hepatitis. In 1998, Niederau et al. conducted a multi-center randomized, placebo-controlled clinical study evaluating the effects of PPC in combination with interferon alpha (IFN) in patients suffering from Hepatitis B and C. IFN is the standard treatment for these diseases, however only 50% of patients with Hepatitis B and 20-30% of patients with Hepatitis C respond to this antiviral drug with long-term normalization of serum aminotransferases. Among patients with hepatitis C that do respond to IFN while under treatment, there is at least a 50% relapse rate. Evidently there is a need for more effective treatment.

In this study 176 patients completed the protocol. All patients were given the same amount of interferon during the 24-week test period. In addition patients were randomly assigned to receive either 1.8 grams per day of PPC or placebo for the same 24 weeks. A biochemical response to therapy was defined as minimum 50% reduction of ALT compared to pre-treatment values.

The results show that PPC increased the response rate to IFN in chronic viral hepatitis C (71% versus 51 % in the placebo group). Prolonged PPC therapy given to responders 24 weeks beyond the cessation of interferon therapy tended to increase the rate of sustained responses in patients with hepatitis C (41% versus 15%). Hepatitis B patients, however, did not have an improved biochemical response to interferon from PPC. The reason why PPC showed beneficial effect in hepatitis C and not in hepatitis B is not clear and will be further investigated.

This study suggests that PPC can be a valuable adjunct to IFN treatment of Hepatitis C as well as be of beneficial use after cessation of IFN therapy in order to increase the chance of sustained response to therapy.

Alcohol and the pancreas
The pancreas is essential to both digestion and glucose regulation. It secretes digestive enzymes into the duodenum for protein, carbohydrate and fat digestion, and produces large amounts of sodium bicarbonate (as found in baking soda) to neutralize stomach acid in the duodenum. The islets of the pancreas produce insulin and the related hormones glucagon and somatostatin.

Pancreatitis-inflammation of the pancreas-is caused primarily by overconsumption of alcohol in about 80% of cases. Ethanol causes severe oxidative stress in the pancreas, probably due to increased production of free radicals and depletion of glutathione and other antioxidants. In particular, both alcohol intake and pancreatitis are associated with rises in the CYP 2E1 enzyme in the pancreas.

The research group that investigated the correction of alcohol-induced liver damage by PPC has recently published research demonstrating the same protective effect in the pancreas (Aleynik SI, Leo MA, Aleynik MK et al., 1999). When rats were given ethanol, markers of oxidative stress in the pancreas rose sharply. However PPC given along with the ethanol prevented this rise, and almost completely alleviated the depletion of pancreatic glutathione caused by ethanol.

The protective effect of PPC on oxidative stress in the pancreas was even more pronounced than these researchers had observed in the liver of baboons fed alcohol. PPC may protect the pancreas from other causes of oxidative stress; as the authors state, PPC "could provide innocuous but effective and orally active antioxidant therapy, not only as shown before for liver injury, but also, as shown here, for early pancreatic changes."

Gastropro, a phosphatidylcholine product, is available from Life Extension


References
Aleynik MK et al.: Polyenylphosphatidylcholine opposes the increase of cytochrome P-4502E1 by ethanol and corrects its iron-induced decrease. Alcohol Clin Exp Res 23(1):96-100, 1999

Aleynik SI, Leo MA, Aleynik MK et al.: Alcohol-induced pancreatic oxidative stress: Protection by phospholipid repletion. Free Radic Biol Med 26 (5/6): 609-619, 1999

Aleynik SI, Leo MA, Takeshige U et al.: Dilinoleoylphosphatidylcholine is the active antioxidant of polyenylphosphatidylcholine. J Investig Med 47(9):507-12, 1999

Anand BS et al.: Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 94(7):1818-22, 1999

Barbagallo CM et al.: Lipoprotein profile and high-density lipoproteins: subfractions distribution in centenarians. Gerontology 44(2):106-10, 1998

Berson A et al.: Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114(4):764-74, 1998

Biagi PL et al.: The effect of dietary polyenylphosphatidylcholine on microsomal delta-6-desaturase activity, fatty acid composition, and microviscosity in rat liver under oxidative stress. J Nutr Biochem 4: 690-94, 1993

Braillon A et al.: Liver in obesity. Gut 26(2): 133-39, 1985

Day CP et al.: The biochemistry of alcohol-induced fatty liver. Biochim Biophys Acta 1215: 33-48, 1994

Dunjic BS et al.: Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic ulcers in rats. Scand J Gastroenterol; 28: 89-94, 1993

Fabia R et al.: Effects of phosphatidylcholine on acetic acid-induced colitis in the rat. Digestion 53: 35-44, 1992

Galli C et al.: Oral polyunsaturated phosphatidylcholine reduces platelet lipid and cholesterol contents in healthy volunteers. Lipids 20(9):561-6, 1985

Holecek M et al.: Effect of polyunsaturated phosphatidylcholine on liver regeneration onset after hepatectomy in the rat. Arzneimittelforschung 42(3): 337-39, 1992

Horejsova M and Urban J: The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings--preliminary study. Cas Lek Cesk 133(12):366-9, 1994

James OFW et al.: Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29: 495-501, 1998

Kesaniemi YA et al.: Effects of dietary polyenylphosphatidylcholine on metabolism of cholesterol and triglycerides in hypertriglyceridemic patients. Am J Clin Nutr 43: 98-107, 1986

Kirsten R et al.: Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients. Int J Clin Pharmacol Ther 32(2): 53-6, 1994

Klimov AN et al.: "Essential" phospholipids versus nicotinic acid in the treatment of patients with type Iib hyperlipoproteinemia and ischemic heart disease. Cardiovasc Drugs Ther 9(6):779-84, 1995

Li J et al.: Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 15(3): 373-381, 1992

Lichtenberger LM et al.: Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Medicine 1(2): 154-58, 1995

Lieber CS et al.: Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology 12(6): 1390-98, 1990

Lieber CS et al.: Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 106: 152-159, 1994

Lieber CS: Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)--a review. Alcohol Clin Exp Res 23(6):991-1007, 1999

Ma X et al.: Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol 24: 604-613, 1996

Navder KP et al.: Polyenylphosphatidylcholine decreases alcoholic hyperlipemia without affecting the alcohol-induced rise of HDL-cholesterol. Life Sci 61(19): 1907-14, 1997

Navder KP et al.: Oxidation of LDL in baboons is increased by alcohol and attenuated by polyenylphosphatidylcholine. J Lipid Res 40(6):983-7, 1999

Niederau C et al.: Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis B and C: A multi-center, randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 45: 797-804, 1998

Oneta CM et al.: Dilinoleoylphosphatidylcholine selectively modulateslipopolysaccharide-induced Kupffer cell activation. J Lab Clin Med 134(5):466-70, 1999

Raskin JB: Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 106(5B), 1999

Stoffel W et al.: Pleomorphic functions of highly unsaturated phospholipids in biological membranes and serum lipoproteins. Med Welt 29(4): 124-31, 1978

Verdery RB et al.: Caloric restriction increases HDL2 levels in rhesus monkeys (Macaca mulatta). Am J Physiol 273(4 Pt 1):E714-9, 1997

Wallace LA et al.: Personal exposures, indoor-outdoor relationships and breath levels of toxic air pollutants measured for 355 persons in New Jersey. EPA 0589, 1989

Wang XD, Andersson R et al.: Phospholipids prevent enteric bacterial translocation in the early stage of experimental acute liver failure in the rat. Scand J Gastroenterol 29:1117-21, 1994

Weltman MD et al.: Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27(1): 128-133, 1998

Wolfe MM et al.: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. NEJM 340(24):1888-99, 1999

Yamada S et al.: Chronic ethanol consumption alters rat liver plasma membranes and potentiates release of alkaline phosphatase. Gastroenterology 88(6): 1799-806, 1985

Yang SQ et al.: Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94: 2557-62, 1997

Back to the Magazine Forum